1. Scrip
  2. >>Business

Finance Watch: VC Mega-Rounds Are Alive And Well

Aspen Neuroscience, MOMA Therapeutics Raised $147.5m And $150m, Respectively

 
• By Mandy Jackson

Private Company Edition: Also, Catalio closed a $381m venture capital fund and OrbiMed’s SEC filings indicate it is in the process of raising $4.75bn across three new funds. Dianthus launched with $100m and Tubulis closed a $63m series B round.

Finance Watch Private Company
• Source: Shutterstock

Venture capital investors continue to show their enthusiasm for drug development, despite the relative pessimism of their peers investing in publicly traded biopharmaceutical companies, by putting their money into a wide array of start-ups and continuing to support multiple VC mega-rounds of $100m or more, including recent series B rounds totaling $147.5m for Aspen Neuroscience, Inc. and $150m for MOMA Therapeutics.

Aspen Neuroscience plans to take its first autologous cell therapy into the clinic with the proceeds of the financing announced...

Read the full article – start your free trial today!

Join thousands of industry professionals who rely on Scrip for daily insights

  • Start your 7-day free trial
  • Explore trusted news, analysis, and insights
  • Access comprehensive global coverage
  • Enjoy instant access – no credit card required
Start Free Trial

Already a subscriber?

More from Financing

More from Business

Syncona Looks To Go Private As Market Decline Deepens

 
• By Andrew McConaghie

While some are calling for Syncona to be wound up, the UK-based company believes many existing and new investors will back the creation of new private fund.

ASCO: Pushing The Frontiers Of ADCs

 
• By Mary Jo Laffler

Antibody-drug conjugates are a major part of the oncology pipeline, and data presented at the American Society of Clinical Oncology meeting highlight the emergence of new technologies.

Top 10 Drugs Q1 2025: Keytruda Dominates; Mounjaro Climbs

 
• By Eleanor Malone

Lilly’s Mounjaro for diabetes rose from sixth to third position among the top-selling drugs in the first quarter of 2025, Rival Ozempic retained second position and Merck & Co’s immuno-oncology blockbuster Keytruda stayed far ahead.